Install
Korea's ENCell partners with Andelyn Biosciences to expand global reach of gene therapy manufacturing BioSpectrum Asia BioSpectrum is an integrated B2B media platform for the healthcare and bioscience industry in the Asia Pacific region.
- 166articles · 30d
- 20+ hour agolatest article
- Aug 18, 2026earliest in window
- 92%with images
- 260avg words
- Medical 109
- Health & Wellness 98
- Health 63
- Business & Industrial 57
- Science & Technology 51
- Economy, Business & Finance 50
- Science & Nature 31
- Finance & Business 22
- cf
- stock screener tool
- highest dollar trading volume
- danaher corporation designs
- cell culture media development services
- cell culture media
- lab-scale protein purification
- aseptic fill finish
- full manufacturing suites
- healthcare filtration solutions
- vertex pharmaceuticals incorporated
- treating cystic fibrosis
- clinical-stage biotechnology company
- lab filtration
- cell line
- companies
- medical news
- stocks
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Taiwan's Horien achieves three Thai FDA Class 4 approvals and secures US patent for Biodegradable Ureteral Stent
6+ day, 7+ hour ago (205+ words) BioSpectrum Asia Taiwan's Horien achieves three Thai FDA Class 4 approvals and secures US patent for Biodegradable Ureteral Stent September 8, 2026 | Tuesday | News Market-entry initiative targets qualified Thai distributors across dental, surgical, wound-care, and regenerative medicine channels Taiwan-based Horien Biochemical Technology has…...
Indonesia steps up Southeast Asia’s outbreak preparedness with pandemic simulation exercise
1+ week, 5+ hour ago (226+ words) September 7, 2026 | Monday | News Indonesia is advancing Southeast Asia’s readiness to tackle a future epidemic or pandemic threat by conducting a landmark pandemic simulation exercise that will strengthen efforts to rapidly develop safe and effective vaccines and other tools against a…...
Korea's IVI inks MoU with Karolinska Institutet to strengthen existing cooperation in vaccine research and education
1+ week, 5+ hour ago (186+ words) September 7, 2026 | Monday | News Building on an established relationship between the two institutions, South Korea-based International Vaccine Institute (IVI) and Karolinska Institutet (KI) have signed a Memorandum of Understanding (MoU) to expand opportunities for academic and scientific exchange within vaccine research. The…...
Korea's Alteogen inks $3.2 B deal with Novartis for development of Hybrozyme™-enabled subcutaneous products
1+ week, 4+ day ago (118+ words) September 3, 2026 | Thursday | News South Korea based Alteogen Inc. has entered into an option and license agreement with Novartis for the development and commercialisation of subcutaneous (SC) products utilising ALT-B4 powered by Alteogen's Hybrozyme™ technology. Under the terms of the agreement,…...
Samsung Bioepis gains marketing approval in Japan for 130mg intravenous infusion of Ustekinumab Biosimilar
1+ week, 4+ day ago (171+ words) September 3, 2026 | Thursday | News South Korea-based Samsung Bioepis has announced the marketing approval of Ustekinumab BS Intravenous Infusion 130mg, a biosimilar referencing Stelara (ustekinumab), indicated for an induction therapy for moderate-to-severe active Crohn’s disease where other treatments are ineffective. This is a…...
Singapore becomes first ASEAN market to subsidise vutrisiran for transthyretin amyloidosis
1+ week, 5+ day ago (228+ words) September 2, 2026 | Wednesday | News Singapore has become the first ASEAN country to provide government subsidies for eligible patients receiving vutrisiran for transthyretin amyloidosis. From 1 September 2026, vutrisiran has been recommended for inclusion under Singapore’s Medication Assistance Fund for eligible patients with stage…...
Malaysia’s Evolving Rare Disease Ecosystem and the Future of Orphan Drug Access
1+ week, 6+ day ago (172+ words) September 1, 2026 | Tuesday | Opinion | By Priyanka Jain, Senior Research Analyst, Health & Wellness, TechVision, Frost & Sullivan Malaysia, with a population of approximately 34.2 million, strengthened its rare disease landscape through the launch of its first National Policy for Rare Diseases (NPRD) on August…...
Five Allocators, No Founders: What the Asia Bio Dealmaking Panel Was Really Pricing
1+ week, 6+ day ago (566+ words) September 1, 2026 | Tuesday | News | By Ankit Kankar | [email protected] A session billed as a conversation about partnering was, on closer inspection, something rather more useful: a pricing signal, delivered by the only people in the room who set prices. Before a…...
Fosun Pharma strengthens innovation pipeline as Henlius and global drug portfolio expand
2+ week, 9+ hour ago (370+ words) August 31, 2026 | Monday | News Fosun Pharma continued to strengthen its innovation-led growth strategy in the first half of 2026, supported by increasing contributions from innovative drugs, pipeline progress and global expansion across its pharmaceutical portfolio. The company recorded operating revenue of RMB20.377 billion…...
Formosa Pharma files European trial application for Kadcyla biosimilar TSY-110
2+ week, 8+ hour ago (229+ words) August 31, 2026 | Monday | News TSY-110 is being co-developed by Formosa Pharmaceuticals and EirGenix as a biosimilar to Roche’s Kadcyla. The reference therapy is used in HER2-positive metastatic and early-stage breast cancer. The planned pivotal study has been designed following regulatory guidance…...